Mandate

Vinge advises international private equity firm Cinven on the acquisition of Envirotainer

July 12, 2018 M&A

Headquartered in Stockholm, Envirotainer designs, manufactures and leases active temperature-controlled containers used primarily for air freighting biopharma products, transporting up to two millions doses of medicine per day. Envirotainer serves c. 600 customers worldwide, including many of the blue-chip global biopharma companies.

With c. 300 employees, Envirotainer operates from regional centres in Stockholm, Frankfurt, Dallas and Singapore, with a portfolio of more than 5,500 leased containers globally. Envirotainer developed and marketed the first container with an active temperature control system in 1995 and since then has significantly invested in technology and its container fleet.

Vinge’s team consisted of partners Christina Kokko and Kristina Ekberg (M&A), Louise Brorsson Salomon and Albert Wållgren (Banking and Finance) together with associates Filip Öhrner, Samra Baytar, Karl Klackenberg, Anna Thoms, Vilhelm Rondahl and Arvid Axelryd (M&A), Linn Adelwald and Agnes Perbo (Banking and Finance), Hedvig Ekdahl, Lisa Hörnqvist and Hayaat Ibrahim (Commercial Agreements), Klara Secher (IP), Sara Strandberg and Sophia Holm (Employment), Johan Cederblad (Environment), Frida Ställborn (Real Estate) and VDR assistant Jessica Öijer.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026